Expanded Indications for ArthroTAK's Sutureless Fixation

ArthroTAK was granted FDA 510(k) clearance for expanded indications, extending the ArthroTAK platform beyond its original shoulder applications into new areas of the body. The clearance marks a milestone for the company, whose ArthroTAK Tendon Anchor Kit already carries FDA clearance for biceps tenodesis procedures. This expanded clearance opens the door for ArthroTAK's 'Drive. Deploy. Done.' fixation technology, a PEEK implant designed for deployment in approximately 45 to 60 seconds without the need for suture management, to reach new anatomical applications. The company's first area of focus under this expanded clearance is the knee, where it will bring its technology to surgeons performing Lateral Extra-articular Tenodesis (LET), a procedure increasingly used alongside ACL reconstruction to improve rotational stability and reduce re-tear rates. This next chapter builds on early momentum from ArthroTAK's limited release for biceps tenodesis, during which the company has completed more than 80 surgical cases. While LET represents ArthroTAK's near-term commercial priority in the knee, the company is continuing to invest in instrumentation and design work intended to extend its sutureless fixation platform to additional anatomical applications throughout the body, including the shoulder, foot and ankle, wrist, and other joints where soft tissue-to-bone fixation is required. 'What excites us most about this clearance isn't just the knee opportunity in front of us; it's the platform it validates,' said Justin J. Kaler, General Manager of ArthroTAK LLC. 'We designed ArthroTAK to be anatomy-agnostic at its core. Knee is our next chapter, but it's one chapter in a much bigger story about how sutureless fixation can change soft tissue attachment across orthopedic surgery.' Source: ArthroTAK, LLC ArthroTAK was granted FDA 510(k) clearance for expanded indications, extending the ArthroTAK platform beyond its original shoulder applications into new areas of the body. The clearance marks a milestone for the company, whose ArthroTAK Tendon Anchor Kit already carries FDA clearance for biceps tenodesis procedures. This expanded clearance... ArthroTAK was granted FDA 510(k) clearance for expanded indications, extending the ArthroTAK platform beyond its original shoulder applications into new areas of the body. The clearance marks a milestone for the company, whose ArthroTAK Tendon Anchor Kit already carries FDA clearance for biceps tenodesis procedures. This expanded clearance opens the door for ArthroTAK's 'Drive. Deploy. Done.' fixation technology, a PEEK implant designed for deployment in approximately 45 to 60 seconds without the need for suture management, to reach new anatomical applications. The company's first area of focus under this expanded clearance is the knee, where it will bring its technology to surgeons performing Lateral Extra-articular Tenodesis (LET), a procedure increasingly used alongside ACL reconstruction to improve rotational stability and reduce re-tear rates. This next chapter builds on early momentum from ArthroTAK's limited release for biceps tenodesis, during which the company has completed more than 80 surgical cases. While LET represents ArthroTAK's near-term commercial priority in the knee, the company is continuing to invest in instrumentation and design work intended to extend its sutureless fixation platform to additional anatomical applications throughout the body, including the shoulder, foot and ankle, wrist, and other joints where soft tissue-to-bone fixation is required. 'What excites us most about this clearance isn't just the knee opportunity in front of us; it's the platform it validates,' said Justin J. Kaler, General Manager of ArthroTAK LLC. 'We designed ArthroTAK to be anatomy-agnostic at its core. Knee is our next chapter, but it's one chapter in a much bigger story about how sutureless fixation can change soft tissue attachment across orthopedic surgery.' Source: ArthroTAK, LLC